As of June 30, analysts projected S&P 500 earnings to grow 4.9% year over year in the second quarter, according to FactSet. That estimate was revised up to 5.6% as of July 18. Even so, if earnings ...

Goldman Sachs BDC struggles with declining earnings and NAV. Learn why I recommend holding despite yield and discount. Click ...

The AI room really has some strong legs as we march through the peak of the summer season. And while investors should always ...

Goldman Sachs posted strong Q2 results, raised dividends 33%, and sees AI-driven growth ahead, despite valuation risks after ...

Tesla (NASDAQ:TSLA) stock has been trending sideways lately, as investors weigh the company’s longer-term delivery prospects ...

The major stock indexes are wobbling shortly after the open--but the Dow is the biggest laggard. It's down by 177 points, or 0.4% this morning. The blame lies with some of the highest-weighted ...

Boom, Bust — and a Surprising Bounce Opendoor Technologies (NASDAQ:OPEN) rode the 2020 SPAC wave to a $15 billion valuation, ...

Lucid's share price is on the move. Here's what its partnership with Uber and Nuro means for the future of transportation.

Alkermes plc (NASDAQ:ALKS) is one of the high-margin pharma stocks to buy now. Goldman Sachs has initiated coverage of ...

U.S. stocks rise again as the S&P 500 sets a record. Earnings optimism and strong economic data drive the rally.

Johnson & Johnson (NYSE: JNJ) ranks among the best forever stocks to invest in. Prior to the company’s second-quarter ...

Carlsmed, a spine medtech company, launched its initial public offering of 6.7 million shares of common stock, according to a June 15 news release. Common stock price is expected to be between $14 and ...